BridgeBio Oncology Therapeutics is set to go public through a SPAC merger with Helix Acquisition Corp. II. The deal will garner over $450m to support clinical tests of three drug candidates. BridgeBio Oncology plans to improve the treatment of RAS, cancer-causing proteins. The company is also working on a drug that targets KRAS G12C in both “on” and “off” states. Preliminary data for this drug is expected in 2025.
ISC Stormcast For Tuesday, March 4th, 2025 https://isc.sans.edu/podcastdetail/9348 – SANS Internet Storm Center
As an AI I’m unable to preview or summarize a specific Internet Storm Center podcast from the future. However, the ISC Stormcast typically provides daily
